The incidence of apnoeic episodes (> 12s) was measured in 30 surgical patients allocated randomly to one of three analgesic regimens and all nursed in a high dependency unit. Ten patients received i.m. morphine (mean 52 (range 30-80) mg), administered on request. The remaining 20 patients received extradural sufentanil as an initial bolus dose of 50 ug followed by a bolus of 10ug, either selfadministered using PCA (10 patients: mean 275 (range 130-450) ug) or administered by a nurse on request (10 patients: 144 (70-200) ug). With i.m. morphine apnoeic episodes were maximal 2-3 h after administration while after extradural sufentanil, apnoeas were maximal within a few minutes. (Br. J. Anaesth. 1994; 73: 634-638) 
Extradural morphine results in respiratory depression occurring unpredictably long after its administration [1, 2] . This late onset is attributed to the low fat solubility of morphine. Morphine persists in slowly circulating cerebrospinal fluid (CSF), with cephalad spread producing late respiratory depression [3] . Opioids with high lipid solubility pass rapidly from the CSF into other tissues leaving little remaining available for cephalad spread [4] but with the potential for significant quantities to pass into the systemic circulation.
Sufentanil is a synthetic opioid related chemically to fentanyl, with a very high lipid solubility (over 1000 times that of morphine). It is the most potent of the commonly available opioids and has a very high affinity for the mu opioid receptor [5] , while its clearance from the CSF has been shown in clinical studies to be rapid [6] . The analgesic efficacy of sufentanil has been demonstrated in a range of surgical procedures, from peripheral orthopaedic procedures [7] to thoracic surgery [8] . Thus respiratory depression after extradural sufentanil may have different characteristics from that associated with less soluble agents. A study of extradural sufentanil administered to volunteers demonstrated marked depression of respiration; however, normal volunteer subjects had no pre-existing or background pain [9] . The effect on respiration in postoperative patients has not been studied in detail.
We have developed a respiratory monitoring system which provides continuous "breath-bybreath" recording of respiratory performance. Oxygen saturation, expired carbon dioxide concentration (used only to detect flow) and chest wall movements are recorded to analyse respiratory patterns and apnoeic episodes.
In this study we have compared the respiratory effects of two regimens of extradural sufentanil with nurse-administered i.m. morphine for the treatment of postoperative pain. To obtain comparable analgesia using dissimilar techniques, patients were allowed full access to the allocated analgesic regimen. In one group this was achieved using a patientcontrolled analgesia (PCA) device to administer the drug through the extradural catheter (group S-P, sufentanil-PCA). In the group without extradural catheters, morphine was administered i.m. on patient request (group M). To ensure prompt treatment, this was done by the nursing staff in a high dependency unit. To test the efficacy of the nursing system and to enable comparisons to be made, a third group was included in which extradural sufentanil was administered by patient request to a nurse (group S-N, sufentanil-nurse) as for the i.m. morphine group.
Patients and methods
Ethics approval was obtained and informed consent from each patient. Patients were included if aged 18-65 yr, weighing 45-100 kg, of ASA grades I-III and undergoing abdominal surgery involving laparotomy. Patients already receiving opioids or antiemetics were excluded. All patients were nursed in a high dependency unit (nurse-patient ratio 0.3). At entry, each patient was allocated randomly to one of the three groups, S-P, S-N or M.
Premedication comprised oral diazepam 10 mg. Anaesthesia was induced with thiopentone 3-5 mg kg" 1 , a non-depolarizing neuromuscular blocking agent was given and the trachea intubated. Mechanical ventilation with nitrous oxide and oxygen was supplemented with i.v. fentanyl (up to 200 ug) and enflurane. In groups S-P and S-N, an extradural catheter was inserted at a level corresponding to the highest dermatome involved in skin incision. Early postoperative analgesia was provided in the recovery ward by a bolus dose of extradural 0.25 % bupivacaine 5-10 ml in groups S-P and S-N, and i.v. morphine as required in group M. When they were awake and stable, patients were moved to the high dependency unit (HDU) and respiratory monitoring was commenced. In groups S-P and S-N an initial dose of sufentanil 50 ug was administered when pain returned. Subsequent doses of 10 ug were given either by a Cardiff Palliator with a lockout time of 10 min (group S-P) or by the nursing staff (group S-N). Group M received i.m. morphine 10-15 mg on request, the dose being decided by the nursing staff, as is the usual practice for this regimen in the HDU.
Arterial oxygen saturation was monitored continuously by pulse oximetry (Novametrix 500) with the low saturation alarm set at 85 %. Movement of gas with respiration was recorded by measurement of carbon dioxide in gas from a nasal cannula (Datex Normocap). This concentration varied reliably between 0 and 4.5% with respiration, even during mouth breathing and speech. Chest wall movements were detected by differential manometry of pressure capsules in the suprasternal notch and lower chest wall; the output signal was related to the amplitude of chest wall excursion. This was used only to indicate chest movement. A continuous paper chart recording of these variables was made from arrival in the HDU until the end of the study. Nurses were asked to administer oxygen by MC mask to any patient in whom arterial saturation decreased to less than 85%, for lh and then to withdraw it. If desaturation recurred the treatment was repeated.
Patients were asked to assess the quality of pain relief every 2 h for 24 h. They scored the worst pain since the previous evaluation using a visual analogue score (100 = worst pain imaginable).
ANALYSIS
The 24-h multichannel chart recording was analysed to provide the following information. (1) The number, times and duration of episodes in which arterial saturation decreased to less then 85%. (2) The number, times and duration of apnoeas of 12 s or more. (3) The times at which successful PGA demands were made by patients in group S-P. Drug administration times for patients in the other groups were obtained from prescription records.
The record of the exact times of drug administration and of the times when apnoeic episodes occurred permitted analysis of the temporal relationship between each administration and the subsequent respiratory events. The null hypothesis that the observed apnoeas were temporally unrelated to administration of analgesic drugs was tested by the creation of a computer model (method developed by, and Apple Macintosh software available from, J.M.S.). For each patient, the times at which postoperative analgesia was administered were noted. The times at which apnoeas occurred were also recorded. Data for central and obstructive events were considered separately. For each apnoeic event, the time elapsed since the most recent administration of opioid was calculated (Td-a). All such times from each treatment group were pooled and frequency distribution histograms of Td-a constructed for each type of apnoea in each treatment group. This procedure was then repeated 100 times for each apnoeic event, replacing the time of the apnoea with computer generated random numbers and the results averaged into dose to random event times (Td-r). The frequency distribution of Td-r was again calculated for each treatment group. This distribution was therefore that which would be expected if the apnoeic events were temporally unrelated to administration of opioids. It was then possible to compare the distribution of Td-a with that of Td-r and draw statistical inferences on differences using binomial distribution. Subtraction of the distribution of Td-r from that of Td-a then produces a graph of the amount by which the observed incidence of apnoeas exceeds the expected incidence plotted against the time elapsed since the most recent dose of drug.
The null hypothesis that the incidence of apnoeas with respect to the time since the last dose of opioid was not different between groups was tested using chi-square for trends [10] . Statistically significant differences in visual analogue scores (mean for each patient) and respiratory variables (totals for each patient) between groups were tested using the Kruskal-Wallis one-way ANOVA (for non-parametric independent samples). Visual analogue pain scores were also compared using the Mann-Whitney U test and from this confidence intervals for the difference between groups were derived.
To calculate the power of the study, parametric ANOVA was performed using 2 and 27 degrees of freedom and the <}> non-centrality variable produced was calculated [11] . This gave an estimate of power using parametric techniques. The power of the Kruskal-Wallis test was found by multiplying this by 3/n [12] .
Results

PATIENT DATA
Six patients were excluded because of inadvertent violation of the study design during administration of the anaesthetic (four patients) or failure of local anaesthetic to produce a demonstrable extradural block in the recovery ward (two patients). The treatment allocations of these patients was returned to the randomization pool so that at the end of the study there were 10 patients in each group. Age, weight, sex and operation type distributions of the patients in each of the three groups were similar (table 1). The surgical procedures were biliary, vascular, gynaecological or gastrointestinal.
DRUG DOSAGE
Patients in group M received a mean total dose of morphine 52 mg (range 30-80 mg) in the 24-h period. Some of this was given i.v. in the recovery ward (mean 7 (0-12) mg). Patients in group S-P received a mean total dose of sufentanil 275 ug (130-^150 ug), whereas patients in group S-N received only 144 jig (70-200 ug). This difference was statistically significantly (P < 0.02) (MannWhitney).
APNOEIC EPISODES
None of the differences in apnoeic episodes between groups was statistically significant. There was no correlation between the total dose of drug administered and total duration of either central or obstructive apnoeas in any of the groups studied. The total number of apnoeas and their durations were similar in each group (table 2). The 4> non-centrality variable produced using parametric ANOVA with 2 and 27 degrees of freedom corresponded to a minimum value for the power of the study of 0.67. Multiplying by 3/7i gives a power of 0.64. From this the probability of a type II error (inappropriately accepting that there is no real difference) is 36 %.
TEMPORAL RELATIONSHIP BETWEEN DOSES AND APNOEIC EVENTS
The incidence of apnoeas was greater after administration of morphine and sufentanil than would be expected by chance (see method). The time course of the excess of apnoeic events is expressed graphically for each of the treatment groups in figure 1. Time zero in each case is the time at which the drug was given.
In the morphine group the incidence of apnoeas increased steadily to a maximum at about 2 h after administration of a dose of i.m. morphine. The difference between the observed incidence and that expected by chance was highly statistically significant at 90 and 120 min (P < 0.001, binomial distribution test for single proportion).
In the sufentanil group the peak incidence of apnoeas occurred within a few minutes of administration of a bolus of sufentanil into the extradural space. By 30 min the incidence had decreased markedly and by 1 h was close to that expected by chance. The initial difference between observed and expected incidences was highly significant (P < 0.005, binomial distribution test for single proportion).
The difference in the pattern of apnoeas with respect to time between the morphine and each of the sufentanil groups was found to be significant (group M vs group S-P, group M vs S-N, both P < 0.001, chi-square test for trends; group S-P vs group S-N, ns). Typical SEM values at 2-24 h were 7.97 for PCA-sufentanil, 7.2 for nurse-administered sufentanil and 7.33 for i.m. morphine.
VISUAL ANALOGUE SCORES
Mean pain scores over the 24-h period are shown in figure 2 . The calculated power of the conclusion that there was no difference in pain scores was 0.73. From this the probability of a type II error (inappropriately accepting that there is no real difference) is 27%. The difference between the groups was also tested using the Mann-Whitney test, and confidence intervals generated from this are shown in table 3.
A correlation between total dose of drug administered over 24 h and mean pain score over 24 h was demonstrable in group S-P (Spearman rank correlation coefficient = 0.69, P < 0.05). In the morphine group and the other sufentanil group, total drug dose and pain scores were unrelated.
ARTERIAL SATURATION
In each group, five of 10 patients required supplementary inspired oxygen for episodes (mainly obstructive) in which arterial saturation decreased to less than 85 % on more than one occasion. In addition, one patient in group S-N had a selfterminating episode of desaturation immediately after the initial bolus dose of sufentanil 50 ug. He subsequently required no oxygen therapy. In designing the study, it was felt to be unethical to allow hypoxaemia to persist untreated and oxygen was administered as required. The durations of the hypoxaemic episodes were thereby shortened by an unknown amount. No attempt is therefore made to present measured durations of hypoxaemia.
Discussion
We have found that in patients who received extradural sufentanil for postoperative pain relief, major interference with respiration was common. Compared with that associated with i.m. morphine, it was similar in magnitude but showed a different time course, with the highest incidence of apnoeas occurring much earlier after administration of sufentanil.
Individual 24-h morphine requirements ranged from 30 to 80 mg. These are similar to total doses reported in studies in which PCA i.v. morphine was used and are also within maximum doses prescribed by i.m. regimens (10-15 mg, 4 hourly as required) [13] . In ward practice, compared with HDU, it is usual for patients to receive much less than the maximum permitted dose, and therefore poorer pain relief.
The requirement for extradural sufentanil by continuous infusion has been reported as a 24-h cumulative total dose of 180-300 ug [14] and the duration of a 50-ug bolus was reported as mean 108 min (range up to 240 min) [15] ; these data predict a mean 24-h requirement of 200 ug with a range from 90 ug (the upper limit was not stated). Therefore, our study agreed closely with previously published work on dose requirements.
The difference in dose between the two sufentanil groups is difficult to explain. The surgical procedures while not identical, were similar, and even among patients who underwent the same procedure, the trend was preserved. A difference in dosage could occur if nursing staff had been excessively conservative but this was clearly not the case as patients in group S-N reported similar pain scores as those in group S-P. It is likely therefore that patients whose drug was administered by nurses, and who also received much sympathetic reassurance and encouragement at the time the drug was given, especially in the HDU, had less pain and need for drug. This phenomenon was pointed out by Beecher [16] in his earliest observations.
The rapidity and brevity of the respiratory effects of extradural sufentanil compared with those of i.m. morphine are in keeping with its physicochemical characteristics. While sufentanil is cleared rapidly from cerebrospinal fluid [6] , minimizing its potential for producing late respiratory depression, it is equally rapidly taken up into blood from the extradural space, making it more likely to produce early respiratory depression. A mean concentration of 1.47 ng ml" 1 (SD 2.78 ng ml" 1 ) was measured in venous blood 2 min after injection of sufentanil 50 ug into the lumbar extradural space in volunteers [9] (assuming a blood volume of 5000 ml) which suggests that on average, more than 10% of the administered dose passes promptly into the bloodstream. Our analysis of the interval between drug administration and apnoeic evens confirms that most episodes of interference with respiration occurred within minutes of administration of a bolus of extradural sufentanil.
The clinical significance of disturbances in respiration and hypoxaemia is uncertain although hypoxaemia with saturation less than 85 % is usually regarded as severe. No patient experienced prolonged respiratory arrest likely to produce permanent damage or death and no patient required naloxone. However, it was necessary to administer oxygen to several patients in every group to avert unacceptable hypoxaemia.
The incidence of apnoeas after i.m. morphine increased steadily and was maximal at 2 h, probably reflecting the profile of the concentration of the poorly lipid soluble morphine inside the blood-brain barrier.
From this detailed study of a small number of patients in which major but self-terminating apnoeas were demonstrated, no inference can be made on the incidence of major life-threatening respiratory events. To establish with 99% confidence that the incidence of fatal respiratory arrest was less than 0.1 %, it would be necessary to study 5000 patients. However, it seems wise to conclude that postoperative oxygen would be a reasonable routine precaution.
The methods used for collection of the visual analogue scores were not blind. The power of the study was not sufficient to enable us to state that there was no difference in quality of pain relief between the groups. The 95 % confidence intervals of the differences in pain scores were all less than 21 % and most were less than 15 %.
PCA sufentanil, although requiring a higher dose than nurse-administered extradural sufentanil for a similar degree of pain relief, was not associated with a greater incidence of severe hypoxaemia or apnoea.
